Healthy male adults
Conditions
Interventions
Ingestion of the test food-A to the subjects, two packages a day (at breakfast and dinner) for 35 days.
Ingestion of the test food-A to the subjects, two packages a day (at breakfast and dinner) for 2
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Healthy male subjects ranging in age from 40 to 60. (2) Subjects who gave informed consent to participate in this trial after being provided with an explanation of the protocol detail.
Exclusion criteria
Exclusion criteria: (1) Subjects with their body temperature of not less than 37.5 degree centigrade at the first coming to clinic. (2) Subjects with any symptoms just like the common cold within two weeks before the first coming to clinic. (3) Subjects with some kind of medical treatment. (4) Subjects who have regularly took in health-specific / functional / health foods, containing a lot of beta-glucan, over three times a week. (5) Subjects who have regularly took in immunostimulation foods, over three times a week. (6) Subjects with previous medical history of drug and/or food allergy. (7) Subjects who are now under the other clinical tests with some kind of medicines/foods, or participated those tests within four weeks after the current trial. (8) Subjects who donated over 200 mL of their whole blood and/or blood components within a month to the current trial. (9) Subjects who donated over 400 mL of their whole blood within the last three months to the current trial. (10) Subjects who are going to be collected over 1200 mL in total of their blood within the last twelve months, after adding the planned sampling blood amounts in this trial. (11) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunostimulation effects | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Thrombogenesis-inhibitory effects 2. Inhibitory effects of blood-glucose level 3. Normalization effects of cholesterol level 4. Safety assessment | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Planning & Sales Department
Outcome results
None listed